TX-SOFTSERVE
30.8.2022 13:06:40 CEST | Business Wire | Press release
SoftServe, a leading digital authority and consulting company, has released the company’s sustainability report for 2021. Prepared in accordance with GRI standards, the report highlights SoftServe’s commitment to sustainability practices as a dedicated member of the United Nations Global Compact. The report provides an overview of the company’s corporate social responsibility (CSR) initiatives, including governance of CSR, IT education, environmental management, and progress in diversity, equity, and inclusion (DE&I).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220830005028/en/
Report demonstrates the company’s commitment to sustainability practices and obligations as a member of the United Nations Global Compact. (Photo: Business Wire)
“SoftServe’s mission is to empower talented people to change the world,” said Chris Baker, CEO. “We stay committed to that mission by making our clients successful, developing our teams and ourselves while innovating every day. This Sustainability Report reflects our ongoing commitment to bringing a sustainable future to our clients, associates, and communities.”
Governance of CSR
SoftServe maintains five cross-functional sustainability councils overseeing individual CSR initiatives. Each council consists of contributors from specific business groups and is overseen by a chairperson and an executive sponsor to ensure effective decision-making processes. As many as 70 leaders throughout the organization are engaged in councils and contribute their efforts to building sustainable practices and scaling impact across the business.
IT Education
IT education and training for qualified specialists remains one of the key areas of corporate social responsibility of the company. SoftServe collaborates with 64 universities around the world, and in 2021 alone, introduced four undergraduate programs with a dual form of education combining theoretical classes with corporate practice.
SoftServe University, which celebrated its 15th anniversary last year, is developing a variety of solutions for both in-house training and for those looking to start an IT career. Out of 2,282 SoftServe IT Academy interns in 2021, most secured a new career with SoftServe - 120% more than a year earlier.
Environment
Last year, SoftServe reduced the number of direct emissions from the production of goods by 55.4% compared to the previous year. The company also introduced a new approach to environmental management and set ambitious environmental goals by 2031. These goals include becoming a zero-carbon business, achieving zero waste, designing environmentally sustainable offices, and developing IT solutions to help meet environmental challenges.
Diversity, Equity, and Inclusion
Principles of diversity, equity, and inclusion drive a culture at SoftServe where every associate has the same opportunity for growth and advancement. The company’s special Diversity, Equity & Inclusion Council works to adhere to these principles and promotes constant progress through operational action.
In addition, SoftServe is a globally responsible employer striving to make each associate’s learning journey as inclusive as possible. Over the last two years, and throughout rapid corporate expansion, SoftServe prioritized accessible office construction and inclusive learning design, and a recent accessibility audit shows an 18% increase in entirely accessible offices.
Click here for more information on SoftServe’s sustainability report.
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize how enterprises and software companies do business. Our end-to-end solutions and expertise deliver innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s marketplace—no matter where you are in your journey.
Visit our website, blog, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
